【摘要】 本研究探讨5-溴汉防己甲素(BrTet)联合柔红霉素(DNR)治疗耐药慢性髓系白血病的潜在可能性及其相关机制。采用流式细胞术检测DNR,BrTet或DNR和BrTet联合作用K562/A02细胞48小时后凋亡率情况;采用RT-PCR法检测对照组K562细胞、耐药K562/A02细胞及DNR或(和)BrTet作用于K562/A02细胞48小时后存活蛋白(survivin)mRNA表达水平;采用Western blot法检测各组细胞survivin蛋白表达水平。结果表明:BrTet与DNR联合作用对K562/A02细胞的诱导凋亡率较其余各组显著升高,同时联合用药组K562/A02细胞survivin mRNA和蛋白的表达较空白对照组和单药组下调,K562/A02细胞survivin表达较K562细胞升高。结论:BrTet联合DNR能有效逆转耐药,促进K562/A02细胞凋亡,其机制可能与survivin表达下调有关。更多还原

【Abstract】 The aim of this study was to investigate the potential benefit of combination therapy with 5-bromotetrandrine(5-BrTet) and daunorubicin(DNR) on chronic leukemia.The apoptosis of K562/A02 cells treated by DNA,BrTet and BrTet combined with DNR for 48 hours was detected by flow cytometry;the expressions levels of survivin mRNA and protein K562/A02 cells treated by DNR,BrTet and BrTet combined with DNR and in untreated K562 cells for 48 hours were measured by RT-PCR and Western blot respectively.The results showed that the combination of BrTet with DNR increased apoptotic rate of K562/A02,down-regulated the expression levels of survivin mRNA and protein in K562/A02 cells as compared with blank control and cells treated by BrTet or DNR alone,the survivin expression in K562/A02 cells was higher than that in K562 cells.It is concluded that the combination of BrTet with DNR can effectively reverse the multidrug resistance of K562/A02 cells,promote the apoptosis of K562/A02 cells,the mechanism of which may be related with down-regulation of survivin expression.Survivin may be a target for the treatment of MDR in hematopoietic malignancies.更多还原